Combination Therapy With Two Biologicals

Combining Biological Therapies in Patients With Inflammatory Bowel Disease: a Finnish Multi-centre Study.

The efficacy and safety of dual biological therapy.

Data of all patients treated with the combination of two biologicals in four Finnish tertiary centres were collected and analysed. Inclusion criteria were simultaneous use of two biological treatments (infliximab, adalimumab, golimumab, vedolizumab or ustekinumab), age 16 years or over and follow-up for at least induction period after introduction of second biological therapy. The primary outcome was effectiveness, defined as remission assessed by physician after at least four months of DBT. The secondary outcome was safety defined by any adverse events or infection complications during DBT.

Inclusion Criteria:

• Simultaneous use of two different biological treatments for IBD.
• Treatment duration with combination therapy for at least for induction period.

Exclusion Criteria:

-Age under 16 years.